Recap: Eli Lilly Q3 Earnings

 

Shares of Eli Lilly LLY fell 3% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share rose 4.05% year over year to $1.54, which missed the estimate of $1.71.

Revenue of $5,741,000,000 up by 4.82% from the same period last year, which missed the estimate of $5,910,000,000.

Outlook

The upcoming fiscal year's EPS expected to be between $7.20 and $7.40.

The upcoming fiscal year's revenue expected to be between $23,700,000,000 and $24,200,000,000.

Conference Call Details

Date: Oct 27, 2020

Time: 09:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/nkvxndgw

Price Action

Company's 52-week high was at $170.75

Company's 52-week low was at $107.54

Price action over last quarter: down 5.92%

Company Profile

Eli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNews
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!